文献速递肝胆胰外科围术期管理与 ERAS

熊去氧胆酸预防Roux-en-Y胃旁路术后新发症状性胆石病的成本效果

Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery.
PubMed 文献 · Br J Surg · 2022-01-01

基于多中心双盲随机安慰剂对照优效性试验数据,对术前无胆石的Roux-en-Y胃旁路术患者进行经济学评价。熊去氧胆酸预防组更可能保持无症状性胆石病(RR 1.06,95%CI 1.02-1.11,P=0.002),QALY增益0.047(95%Bca CI 0.007-0.088,P=0.022),成本差异不显著但有利于熊去氧胆酸,成本效果概率至少0.872,结论为具有成本效果。

要点

  • 熊去氧胆酸预防可提高RYGB术后无胆石患者无症状性胆石病生存率(RR 1.06)。
  • QALY增益0.047,成本效果概率至少0.872,支持预防性用药。
  • 成本差异不显著,但点估计有利于熊去氧胆酸预防。

核心结论

  • 对于术前无胆石的Roux-en-Y胃旁路术患者,熊去氧胆酸预防具有成本效果。

研究设计与样本

  • 基于多中心、双盲、随机安慰剂对照优效性试验数据的经济学评价,针对术前无胆石且接受RYGB的亚组患者。

主要发现

  • 熊去氧胆酸预防组保持无症状性胆石病的可能性更高(相对危险度1.06,95%CI 1.02-1.11,P=0.002)。
  • 校正基线健康效用差异后,QALY增益为0.047(95%Bca CI 0.007-0.088,P=0.022)。
  • 医疗系统视角成本差异为-€356(95%Bca CI -€1573至761),社会视角为-€1392(-3807至917),均无统计学显著性。
  • 熊去氧胆酸预防具有成本效果的概率至少为0.872。

临床怎么用

  • 可考虑对术前无胆石的RYGB患者预防性使用熊去氧胆酸以预防症状性胆石病,并具有成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim was to evaluate the cost-effectiveness and cost-utility of ursodeoxycholic acid (UDCA) prophylaxis for the prevention of symptomatic gallstone disease after Roux-en-Y gastric bypass (RYGB) in patients without gallstones before surgery. METHODS: Data from a multicentre, double-blind, randomized placebo-controlled superiority trial were used. Patients scheduled for laparoscopic RYGB or sleeve gastrectomy were randomized to receive 900 mg UDCA or placebo for 6 months. Indicated by the clinical report, prophylactic prescription of UDCA was evaluated economically against placebo from a healthcare and societal perspective for the subgroup of patients without gallstones before surgery who underwent RYGB. Volumes and costs of in-hospital care, out-of-hospital care, out-of-pocket expenses, and productivity loss were assessed. Main outcomes were the costs per patient free from symptomatic gallstone disease and the costs per quality-adjusted life-year (QALY). RESULTS: Patients receiving UDCA prophylaxis were more likely to remain free from symptomatic gallstone disease (relative risk 1.06, 95 per cent c.i. 1.02 to 1.11; P = 0.002) compared with patients in the placebo group. The gain in QALYs, corrected for a baseline difference in health utility, was 0.047 (95 per cent bias-corrected and accelerated (Bca) c.i. 0.007 to 0.088) higher (P = 0.022). Differences in costs were -€356 (95 per cent Bca c.i. €-1573 to 761) from a healthcare perspective and -€1392 (-3807 to 917) from a societal perspective including out-of-pocket expenses and productivity loss, both statistically non-significant, in favour of UDCA prophylaxis. The probability of UDCA prophylaxis being cost-effective was at least 0.872. CONCLUSION: UDCA prophylaxis after RYGB in patients without gallstones before surgery was cost-effective.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Haal S, Guman MSS, de Brauw LM, et al. Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery. Br J Surg. 2022. PMID: 35979609. doi:10.1093/bjs/znac273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。